Skip to main content

A decade from discovery to therapy: Lingo-1, the dark horse in neurological and psychiatric disorders

Journal Article


Download full-text (Open Access)

Abstract


  • Leucine-rich repeat and immunoglobulin domain-containing protein (Lingo-1) is a potent negative regulator of neuron and oligodendrocyte survival, neurite extension, axon regeneration, oligodendrocyte differentiation, axonal myelination and functional recovery; all processes highly implicated in numerous brain-related functions. Although playing a major role in developmental brain functions, the potential application of Lingo-1 as a therapeutic target for the treatment of neurological disorders has so far been under-estimated. A number of preclinical studies have shown that various methods of antagonizing Lingo-1 results in neuronal and oligodendroglial survival, axonal growth and remyelination; however to date literature has only detailed applications of Lingo-1 targeted therapeutics with a focus primarily on myelination disorders such as multiple sclerosis and spinal cord injury; omitting important information regarding Lingo-1 signaling co-factors. Here, we provide for the first time a complete and thorough review of the implications of Lingo-1 signaling in a wide range of neurological and psychiatric disorders, and critically examine its potential as a novel therapeutic target for these disorders.

Publication Date


  • 2015

Citation


  • Andrews, J. L. & Fernandez-Enright, F. (2015). A decade from discovery to therapy: Lingo-1, the dark horse in neurological and psychiatric disorders. Neuroscience and Biobehavioral Reviews, 56 97-114.

Scopus Eid


  • 2-s2.0-84936865701

Ro Full-text Url


  • http://ro.uow.edu.au/cgi/viewcontent.cgi?article=4032&context=smhpapers

Ro Metadata Url


  • http://ro.uow.edu.au/smhpapers/3010

Has Global Citation Frequency


Number Of Pages


  • 17

Start Page


  • 97

End Page


  • 114

Volume


  • 56

Place Of Publication


  • United Kingdom

Abstract


  • Leucine-rich repeat and immunoglobulin domain-containing protein (Lingo-1) is a potent negative regulator of neuron and oligodendrocyte survival, neurite extension, axon regeneration, oligodendrocyte differentiation, axonal myelination and functional recovery; all processes highly implicated in numerous brain-related functions. Although playing a major role in developmental brain functions, the potential application of Lingo-1 as a therapeutic target for the treatment of neurological disorders has so far been under-estimated. A number of preclinical studies have shown that various methods of antagonizing Lingo-1 results in neuronal and oligodendroglial survival, axonal growth and remyelination; however to date literature has only detailed applications of Lingo-1 targeted therapeutics with a focus primarily on myelination disorders such as multiple sclerosis and spinal cord injury; omitting important information regarding Lingo-1 signaling co-factors. Here, we provide for the first time a complete and thorough review of the implications of Lingo-1 signaling in a wide range of neurological and psychiatric disorders, and critically examine its potential as a novel therapeutic target for these disorders.

Publication Date


  • 2015

Citation


  • Andrews, J. L. & Fernandez-Enright, F. (2015). A decade from discovery to therapy: Lingo-1, the dark horse in neurological and psychiatric disorders. Neuroscience and Biobehavioral Reviews, 56 97-114.

Scopus Eid


  • 2-s2.0-84936865701

Ro Full-text Url


  • http://ro.uow.edu.au/cgi/viewcontent.cgi?article=4032&context=smhpapers

Ro Metadata Url


  • http://ro.uow.edu.au/smhpapers/3010

Has Global Citation Frequency


Number Of Pages


  • 17

Start Page


  • 97

End Page


  • 114

Volume


  • 56

Place Of Publication


  • United Kingdom